NIVOLUMAB (Opdivo) prior authorization at Humana
Submission criteria, P2P prep, and appeal path if denied — for prescribers and PA staff
Humana requires Programmed Death Receptor-1 Blocking Antibody prior-authorization documentation for NIVOLUMAB (Opdivo): a diagnosis with ICD-10 code, documented step-therapy history, and prescriber attestation of medical necessity. Standard PA decisions return in 30 days; if denied, prescribers and members have 60 days to appeal.
The PA criteria you'll need to meet
Humana reviews NIVOLUMAB (Opdivo) prior authorizations against its medical policy for Programmed Death Receptor-1 Blocking Antibody. Humana-specific context: Heavily Medicare Advantage focused. MA-specific appeal track (42 CFR Part 422 Subpart M) applies — 60 days to request reconsideration, NOT the 180 days for commercial plans. Auto-forward to IRE (Maximus) if Humana misses deadline.
Documentation packet checklist
- Chart note with diagnosis (ICD-10 code) and clinical severity markers
- Documented failure of, contraindication to, or intolerance of step-therapy alternatives in Programmed Death Receptor-1 Blocking Antibody
- Prior treatment history including dosing, duration, and reason for discontinuation
- Relevant labs, imaging, or assessment scores supporting medical necessity
- Prescriber attestation linking the FDA-approved indication to the patient's presentation
- Humana's medical policy URL referenced in the cover letter
Humana's common denial patterns
Pre-empting these patterns in the initial submission cuts rework and shortens time-to-approval:
- MA plan step therapy on Part B drugs
- Skilled nursing facility days
- Prior auth on specialty drugs
- OON emergency reduction
NIVOLUMAB (Opdivo)-specific denial patterns and context
Across payers (not just Humana), NIVOLUMAB (Opdivo)draws a distinct set of denial reasons rooted in the drug's label, REMS, and competitive landscape:
- Off-label indication denial despite NCCN compendium support
- Combination with ipilimumab denied as duplicate therapy
- Adjuvant use denial citing 'no overall survival data'
- Continuation beyond 2 years
Brand: Opdivo. PD-1 inhibitor approved across 20+ indications. Opdualag (nivolumab + relatlimab) is the first LAG-3 combination. Subcutaneous nivolumab (Opdivo Qvantig) FDA-approved December 2024 — appeal denials of subQ formulation citing IV-only preference.
Manufacturer patient-assistance program: BMS Access Support — relevant when a Humana denial sticks and the patient needs bridge access while appealing.
How Humana approaches Immune checkpoint inhibitors PAs
Humana's Immune checkpoint inhibitors reviewer typically anchors NIVOLUMAB (OPDIVO) prior-auth decisions on prior auth on specialty drugs. Pharmacy-benefit review for NIVOLUMAB (OPDIVO) at Humana is routed through Humana Pharmacy Solutions (in-house, Medicare Advantage-focused). The 30-day standard review window starts when the prior-authorization request is received with all required documentation — incomplete packets pause the clock and add 5-10 days to time-to-approval, after which the 60-day internal-appeal window begins from the denial date. Off-label oncology appeals at Humana carry significantly higher reversal rates when the appeal letter cites the specific NCCN compendium evidence-block category (2A or above) rather than peer-reviewed citations alone. Humana is domiciled in KY, so unresolved appeals escalate to the KY insurance department's external-review program for fully-insured policies (self-funded ERISA plans route to the DOL EBSA instead). Heavily Medicare Advantage focused.
If the PA is denied
Humana gives prescribers and members 60 days to file an internal appeal. Standard appeal decisions return within 30 days. Submit through the provider portal (https://www.humana.com/provider) with the same packet plus a peer-reviewed citation supporting NIVOLUMAB (Opdivo)for the patient's indication.
Medicare Advantage path: if Humana misses the appeal deadline the case auto-forwards to the Independent Review Entity (Maximus). Time-to-decision favors clinicians who request expedited review with a 72-hour clock when the delay risks harm.
Humana as a Medicare Advantage organization operates under 42 CFR Part 422 Subpart D for organization determinations: a standard (non-urgent) pre-service decision is due within 7 calendar days under CMS-0057-F (effective January 1, 2026; reduced from the prior 14-day standard), an expedited decision within 72 hours, and Part B drug decisions within 72 hours under the 2023 step-therapy rule extension. For NIVOLUMAB (OPDIVO), the Part B vs Part D coverage determination is the threshold question — Part B drugs (provider-administered) follow the organization-determination track under 42 CFR §422.566, while Part D drugs follow the coverage-determination track under 42 CFR §423.566. Missed deadlines auto-forward to the Independent Review Entity (Maximus Federal Services) without member action — track the calendar carefully because this is the most reliable lever in MA appeals.
Helping a patient appeal the denial directly? See the consumer guide: How to appeal a Humana denial on DenialHelp.
Contact Humana
- Provider portal: https://www.humana.com/provider
Frequently asked questions
What documentation does Humana need for NIVOLUMAB (Opdivo) prior auth?
Humana's typical PA packet for NIVOLUMAB (Opdivo): (1) chart note documenting the indication and prior-treatment failures, (2) supporting lab/imaging where indicated, (3) prescriber attestation that step-therapy alternatives were tried or contraindicated, (4) FDA-approved indication mapped to ICD-10 diagnosis. For Programmed Death Receptor-1 Blocking Antibody, expect clinical-criteria documentation specific to this class.
What's the turnaround time at Humana?
Standard NIVOLUMAB (Opdivo) PA decisions at Humana: 30 days. Urgent / expedited (member's life or function at risk): 72 hours under 45 CFR §147.136. Medicare Advantage adds the 14-day extension rule under 42 CFR Part 422.
What does Humana most often reject NIVOLUMAB (Opdivo) for?
Across Humana's book the common rejection patterns include: MA plan step therapy on Part B drugs; Skilled nursing facility days; Prior auth on specialty drugs. For NIVOLUMAB (Opdivo) specifically, expect step-therapy challenges and indication-restriction reviews when the use is at the edge of the FDA label or off-label.
Does Humana cover off-label use of NIVOLUMAB (OPDIVO) supported by NCCN compendium?
Humana generally follows the NCCN Drugs & Biologics Compendium for oncology coverage — Category 1, 2A, and most 2B recommendations are reimbursable in most plans under Medicare-aligned and many commercial policies. For off-label NIVOLUMAB (OPDIVO), cite the NCCN compendium entry by version + table number, name the evidence-block category, and attach the specific clinical-trial or meta-analysis reference. 30-day decision; 60 days to appeal if denied. Adjuvant and combination uses face heavier scrutiny than first-line metastatic. Pharmacy-benefit handling is routed through Humana Pharmacy Solutions (in-house, Medicare Advantage-focused). External-review escalation for Humana fully-insured policies sits with the KY insurance department.
How do I prep for a peer-to-peer with Humana on NIVOLUMAB (Opdivo)?
Lead with the FDA-approved indication and the specific clinical criteria the policy lists. Have the patient's chart open, document number, and policy URL on screen. State your name and credentials, the policy number, the indication, and the documented failures of step-therapy alternatives. Keep notes — if the P2P reviewer overturns, get the decision in writing.
Related PA criteria
Generate the NIVOLUMAB (Opdivo) PA packet
Open ApprovalHelp — generate a NIVOLUMAB (Opdivo) prior-auth packet tailored to Humana's criteria, with prescriber attestation and step-therapy documentation pre-filled.
Get started →Contact: hello@approvalhelp.com